Thank you. The drug used is Lucentis and it is not the drug that has changed, it is the funding. Most jurisdictions were not funding this procedure. A lot of our residents -- not a lot, there are about 30 that were doing this -- were going to Alberta because they were able to go to a clinic where the cost was paid for. So we have just discovered these numbers because Alberta has made a change, put it on their formulary and, therefore, they are not being covered by this clinic. Because we didn’t know and approved the preapproval, it has been hard to find the exact numbers. We are looking at two things. The business case for the cost will be quite significant to add this to the formulary and in particular when you include the medical travel costs. We are also looking at, because the procedure is an injection and requires training and equipment, whether we could actually do that at Stanton. So all of that is being reviewed and we should be able to come forward to the Minister quite soon with that.

This often happens when you have a new use of a drug or a new procedure, that it takes a while in different jurisdictions, add it to their formula over time. But the other issue on this is that if you do it, you actually only approve it for so many injections because it does not treat all people. We didn’t have any control. You would set a stage of three

injections and then see for progress. If there wasn’t, it wouldn’t be an automatic continuation. All of those are being done within the department and also with the medical advisor as to what the actual protocol should be and if we can do it. Thank you.